Dapagliflozin Mitigates Cardiotoxic Effects of Sunitinib via AMPKα-PPARα

Overview

Dapagliflozin has been shown to mitigate sunitinib-induced cardiotoxicity through the AMPKα-PPARα pathway, enhancing renal cell carcinoma sensitivity to sunitinib. This study highlights the potential of dapagliflozin as a therapeutic agent to reduce cardiac side effects associated with cancer treatment.

Background

Cardiotoxicity from cancer therapies, particularly tyrosine kinase inhibitors like sunitinib, poses significant risks to patients, including left ventricular dysfunction and heart failure. Understanding the mechanisms of such toxicity is crucial for developing safer treatment options. Dapagliflozin, initially used for diabetes management, has demonstrated cardioprotective effects, warranting investigation into its role in mitigating cardiotoxicity in cancer therapies.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Dapagliflozin effectively reduced sunitinib-induced left ventricular dysfunction in mice.
• The cardioprotective effects of dapagliflozin were mediated through the AMPKα-PPARα pathway.
• Sunitinib treatment led to myocardial cell apoptosis and oxidative stress in both immunodeficient and immunocompetent mice.
• Dapagliflozin's protective effects were independent of its SGLT2 inhibition.
• Understanding the mechanisms of sunitinib-induced cardiotoxicity is essential for improving patient outcomes.

Clinical Implications

Clinicians should consider the potential of dapagliflozin as an adjunct therapy to reduce cardiotoxicity in patients undergoing treatment with sunitinib. Further research is needed to validate these findings in clinical settings and explore the broader implications for cancer therapy management.

Conclusion

This study provides evidence that dapagliflozin may serve as a protective agent against sunitinib-induced cardiotoxicity, highlighting a novel therapeutic approach in managing cardiac risks associated with cancer treatments.

References

1. Basic Research in Cardiology, 2024 -- Sodium–glucose cotransporter 2 inhibitors: Implications for cancer patients from diabetes management to cardiovascular and renal protection
2. The ASCO Post, 2012 -- Options Shifting for First-line Treatment of Renal Cell Carcinoma
3. The ASCO Post, 2016 -- Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
4. Basic Research in Cardiology, 2024 -- Exploring the Impact of Dapagliflozin on Atrial Fibrillation: Can Higher Doses Provide Class I Antiarrhythmic Benefits?
5. EAU Guidelines on RCC, 2026 -- DISEASE MANAGEMENT
6. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
7. The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies | Global Heart
8. EAU Guidelines on RCC - DISEASE MANAGEMENT
9. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
10. The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies | Global Heart